The short version of tirzepatide fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-05-28 and is reviewed periodically as new material appears.
Development of tirzepatide took place under a research program that sought to test whether simultaneous engagement of two incretin receptors would produce greater metabolic effects than single-receptor agonism. Clinical trials were organized into the SURPASS series for type 2 diabetes and the SURMOUNT series for obesity and weight management. Regulatory clearance for type 2 diabetes came in 2022 in the United States, followed by approval for chronic weight management in 2023. The trial programs reported reductions in glycated hemoglobin and body weight relative to comparators, though long-term cardiovascular and durability data continue to accumulate.
The peptide backbone contains 39 amino acids and includes alpha-aminoisobutyric acid residues, which are not among the standard proteinogenic set. A C20 fatty diacid moiety is attached through a linker, allowing the compound to bind serum albumin and extend its circulation time. This albumin binding is the main reason the molecule supports once-weekly administration rather than more frequent dosing. The measured molecular mass is approximately 4,813 daltons, placing it firmly in the peptide rather than small-molecule class.
Clinical research programs have evaluated tirzepatide in adults with type 2 diabetes and in adults with obesity or excess weight. Trials generally reported reductions in glycated hemoglobin and body weight across treatment periods of several months. Since these studies enrolled defined populations under controlled conditions, the findings describe group averages rather than individual outcomes. Open questions include the durability of effects after treatment stops, variation among subgroups, and the long-term consequences of sustained dual receptor stimulation. Published trial summaries should be consulted for exact measurements rather than secondary accounts.
Tirzepatide is a synthetic peptide built from 39 amino acid residues. Its backbone derives from the native glucose-dependent insulinotropic polypeptide sequence, altered at several positions to resist enzymatic cleavage. A fatty diacid group attached through a linker extends plasma residence time by promoting reversible binding to serum albumin. The molecule carries a net negative charge near physiological pH and has a reported molecular weight close to 4813 daltons. These features separate it from shorter incretin analogs and account for its prolonged dosing interval.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Modified synthetic peptide | 39-residue backbone with non-natural residues |
| Receptor targets | GIP and GLP-1 | Dual incretin receptor agonist |
| Approximate molecular mass | 4,813 Da | Calculated from the peptide sequence |
| Administration route | Subcutaneous injection | Weekly schedule in approved products |
| Albumin binding | Present | Mediated by a C20 fatty diacid side chain |
At the receptor level, tirzepatide activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. Both belong to the class B family of G protein-coupled receptors and signal largely through cyclic AMP accumulation. The compound binds the two receptors with differing affinity, and the pattern of signaling at each site is described in the literature as biased rather than simply proportional to occupancy. Tissues carrying these receptors include pancreatic islets, adipose tissue, the central nervous system, and the gastrointestinal tract. The relative weight of each receptor population in producing metabolic effects continues to be studied.
Published work supports the view that engaging two incretin receptors produces changes in glucose handling and body weight larger than those seen with single-receptor activation. Why that difference arises is not fully settled. Open questions include how much of the observed weight effect depends on central versus peripheral signaling, and whether the two receptors form interacting complexes. Most reported findings come from controlled trials and animal models, and translation between species is imperfect. Further research is expected to refine these points over time.
该化合物的名称与结构由国际非专利名称体系统一维持，不同文献中出现的同义写法主要在拼写顺序或盐形式描述上不同。研究者通常通过受体结合实验、细胞内环磷酸腺苷积累测定以及动物模型来确认其双激动活性。相当一部分分子层面的细节——例如两条受体通路之间的信号交叉作用——尚处于开放问题状态。
当前公开资料把 tirzepatide 归为肠促胰素类受体双重激动剂。它并非激素天然变体，而是经过序列改造的工程化肽。其分子量、等电点与疏水性等基础参数已在药典和化学数据库中收录，可作为分析检测和质量研究的参照。
Tirzepatide is a synthetic peptide composed of 39 amino acids. It acts as a dual agonist at two incretin receptors, the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. The molecule was designed by modifying the native sequence of glucose-dependent insulinotropic polypeptide to improve metabolic stability and extend its circulation time. Its structure includes several non-natural amino acid residues and a fatty acid side chain. These features distinguish it from earlier single-receptor incretin analogs studied in the same period.
The compound first appeared in the scientific literature as an investigational agent for type 2 diabetes. Clinical development proceeded through phase 1, phase 2, and phase 3 programs that measured glycemic control as a primary endpoint while recording body weight as a secondary outcome. Regulatory approval in the United States followed in 2022 for glycemic control, and a separate indication for chronic weight management was added later. Subsequent trials have examined cardiovascular outcomes in adults with elevated cardiovascular risk. Debates continue over how much of the observed effect derives from each receptor arm.
Structural work on the molecule centers on a C20 fatty diacid moiety attached through a linker to the peptide backbone. This side chain promotes reversible binding to serum albumin, which slows renal clearance and supports a prolonged action profile. The peptide backbone incorporates aminoisobutyric acid substitutions that limit recognition by digestive enzymes. Together these modifications produce a molecule that is stable enough for subcutaneous delivery but still dependent on careful manufacturing control. Analytical characterization of the active pharmaceutical ingredient typically follows the conventions used for other synthetic peptides.
=== Operation Inherent Resolve === On 19 December 2014, Stars & Stripes, a daily military newspaper, announced 1,000 soldiers from the 82nd Airborne's 3rd Brigade Combat Team would deploy to Iraq to train, advise, and assist Iraq's Security Forces. On 3 November 2016, it was reported that 1,700 soldiers from the 2d Brigade Combat Team will deploy to the US Central Command area of responsibility in Iraq, to take part in Operation Inherent Resolve. They will replace the 2d Brigade Combat Team, 101st Airborne Division and will advise and assist Iraqi Security Forces currently trying to retake Mosul from ISIS fighters. On 27 March 2017, it was reported that 300 paratroopers from the 82nd Airborne's 2nd Brigade Combat Team will temporarily deploy to northern Iraq to provide additional advise-and-assist combating ISIS, particularly to speed up the offensive against ISIS in Mosul. On 31 December 2019, approximately 750 soldiers from the 82nd Airborne's Immediate Response Force were authorized to be deployed to Iraq in response to events which saw the United States' embassy in the country stormed. From the start of January 2017 to September 2017, the division suffered the loss of five paratroopers killed in action.
==== Male–male competition ==== Most cephalopods engage in aggressive sex: a protein in the male capsule sheath stimulates this behavior. They also engage in male–male aggression, where larger males tend to win the interactions. When a female is near, the males charge one another continuously and flail their arms. If neither male backs away, the arms extend to the back, exposing the mouth, followed by the biting of arm tips. During mate competition males also participate in a technique called flushing. This technique is used by the second male attempting to mate with a female. Flushing removes spermatophores in the buccal cavity that was placed there by the first mate by forcing water into the cavity. Another behavior that males engage in is sneaker mating or mimicry – smaller males adjust their behavior to that of a female in order to reduce aggression. By using this technique, they are able to fertilize the eggs while the larger male is distracted by a different male. During this process, the sneaker males quickly insert drop-like sperm into the seminal receptacle.
Although historically stepfamilies are built through the institution of marriage and are legally recognized, it is currently unclear if a stepfamily can be both established and recognized by less-formal arrangements, such as when a man or woman with children cohabits with another man or woman outside of marriage. This relationship is becoming more common in all Western countries. There appear to be many cultures in which these families are recognized socially as de facto families. However, in modern Western culture it is often unclear as to what, if any, social status and protection they enjoy in law. The stepparent is a "legal stranger" in most of the U.S. and has no legal right to the minor child no matter how involved in the child's life they are. The biological parents (and, where applicable, adoptive parents) hold that privilege and responsibility. If the biological parent does not give up their parental rights and custody of the child, the other parent's subsequent marriage cannot create a parental relationship without the biological parent's written consent before a "child" reaches adulthood. In most cases, the stepparent can not be ordered to pay child support. Stepparents generally do not have the authority to give legal consent to medical treatment for a stepchild, unless the stepparent has legally adopted the child or been designated a legal guardian. A child's parents or legal guardians may sign a statement authorizing a third party to consent to medical care.
The active site consists of four copper centers, which adopt structures classified as type I, type II, and type III. A tricopper ensemble contains types II and III copper (see figure). It is this center that binds O2 and reduces it to water. Each Cu(I,II) couple delivers one electron required for this conversion. The type I copper does not bind O2, but functions solely as an electron transfer site. The type I copper center consists of a single copper atom that is ligated to a minimum of two histidine residues and a single cysteine residue, but in some laccases produced by certain plants and bacteria, the type I copper center contains an additional methionine ligand. The type III copper center consists of two copper atoms that each possess three histidine ligands and are linked to one another via a hydroxide bridging ligand. The final copper center is the type II copper center, which has two histidine ligands and a hydroxide ligand. The type II together with the type III copper center forms the tricopper ensemble, which is where dioxygen reduction takes place. The type III copper can be replaced by Hg(II), which causes a decrease in laccase activity. Cyanide removes all copper from the enzyme, and re-embedding with type I and type II copper has been shown to be impossible. Type III copper, however, can be re-embedded back into the enzyme. A variety of other anions inhibit laccase. Laccases affects the oxygen reduction reaction at low overpotentials. The enzyme has been examined as the cathode in enzymatic biofuel cells.
Once the blood reaches the heart, it moves first into the right atrium, then the right ventricle to be pumped through the lungs for further gas exchange of carbon dioxide waste for oxygen. Oxygenated blood then flows from the lungs through the left atrium to the left ventricle where it is pumped out to the body.
Sources: en.wikipedia.org
In August 1965, Singapore was separated from the federation and became an independent country. Malaysia is tropical and is one of 17 megadiverse countries; it is home to numerous endemic species. The country is multiethnic and multicultural, which has a significant effect on its politics. About half the population is ethnically Malay, with minorities of Chinese, Indians, and indigenous peoples. The Bumiputra policy grants the Malay majority a constitutionally enshrined privileged status over Malaysian citizens who are Chinese or Indians via affirmative action measures. The official language is Malaysian Malay, a standard form of the Malay language. English remains an active second language. While recognising Islam as the official religion, the constitution grants freedom of religion to non-Muslims though conversion out of Islam is forbidden while conversion to it is allowed. The government is modelled on the Westminster parliamentary system, and the legal system is based on common law. The head of state is an elected monarch, chosen among the nine state rulers every five years. The head of government is the prime minister. The country's economy was once heavily reliant on agriculture and primary commodities but is now driven by the services and manufacturing sectors. Malaysia ranks highly in peacefulness and passport strength and has a newly industrialised economy that is relatively open and state-oriented.
== As a lipid biomarker == Archaeol in the sediments typically originates from the hydrolysis of archaea membrane phospholipids during diagenesis. Due to its high preservation potential, it is often detected and used by organic geochemists as a biomarker for archaea activity, especially for methanogen biomass and activity. As a methanogen proxy, it is used by Michinari Sunamura et al. to directly measure the methanogens in the sediments of Tokyo Bay, and also used by Katie L. H. Lim et al. as an indicator of methanogenesis in water-saturated soils. C. A. McCartney et al. used it as a proxy for methane production in cattle. In the meantime, it is also used to help understand ancient biogeochemistry. It was used as a biomarker by Richard D. Pancost et al. in order to reconstruct the Holocene biogeochemistry in ombrotrophic peatlands. A pilot study led by Ian D. Bull et al. also used archaeol as a biomarker to reveal the differences between fermenting digestive systems in foregut and hindgut of ancient herbivorous mammals. Additionally, because of different degradation kinetics of intact archaeol and caldarchaeol, the ratio of archaeol to caldarchaeol was proposed as a salinity proxy in highland lakes, providing a tool for paleosalinity studies. Archaeol can also get hydrolyzed in some cases, with its side chains preserved as phytane or pristane, depending on the redox conditions.
cloning The process of producing, either naturally or artificially, individual organisms or cells which are genetically identical to each other. Clones are the result of all forms of asexual reproduction, and cells that undergo mitosis produce daughter cells that are clones of the parent cell and of each other. Cloning may also refer to biotechnology methods which artificially create copies of organisms or cells, or, in molecular cloning, copies of DNA fragments or other molecules.
==== Experiment in bacteria ==== Lunzer et al. tested the outcome of swapping divergent amino acids between two orthologous proteins of isopropylmalate dehydrogenase (IMDH). They substituted 168 amino acids in Escherichia coli IMDH that are wild type residues in IMDH Pseudomonas aeruginosa. They found that over one third of these substitutions compromised IMDH enzymatic activity in the Escherichia coli genetic background. This demonstrated that identical amino acid states can result in different phenotypic states depending on the genetic background. Corrigan et al. 2011 demonstrated how Staphylococcus aureus was able to grow normally without the presence of lipoteichoic acid due to compensatory mutations. Whole genome sequencing results revealed that when Cyclic-di-AMP phosphodiesterase (GdpP) was disrupted in this bacterium, it compensated for the disappearance of the cell wall polymer, resulting in normal cell growth. Research has shown that bacteria can gain drug resistance through compensatory mutations that do not impede or having little effect on fitness. Previous research from Gagneux et al. 2006 has found that laboratory grown Mycobacterium tuberculosis strains with rifampicin resistance have reduced fitness, however drug resistant clinical strains of this pathogenic bacteria do not have reduced fitness. Comas et al. 2012 used whole genome comparisons between clinical strains and lab derived mutants to determine the role and contribution of compensatory mutations in drug resistance to rifampicin.
Sources: en.wikipedia.org
It binds and activates both the GIP and GLP-1 receptors, making it a dual incretin receptor agonist. Single-receptor GLP-1 agonists act on one target only. The dual profile is the defining pharmacological feature of the molecule.
A fatty diacid side chain promotes reversible binding to serum albumin. This association slows renal clearance and protects the peptide from rapid enzymatic degradation. The result is a prolonged circulation time that supports weekly administration.
The first regulatory approval, for type 2 diabetes, was granted in the United States in 2022. An additional approval for chronic weight management followed in 2023. Availability and approved indications vary by country and are set by each national regulator.
It is a synthetic peptide that activates both the GIP and GLP-1 receptors, making it a dual agonist. Approved products are given by injection rather than by mouth. It is not a small molecule and does not belong to the older sulfonylurea or thiazolidinedione families.